2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Brivaracetam in epilepsy<br />
New Phase 3 trial started – first <strong>results</strong> H1 2013<br />
Phase 3 trial currently recruiting<br />
• Refractory patient population (≥16 to 80 <strong>year</strong>s ) with partial<br />
onset seizures (POS)<br />
• 720 patients across 120 sites worldwide<br />
• Multicenter, placebo-controlled, randomized efficacy trial<br />
Placebo, brivaracetam 100mg/day, brivaracetam 200mg/day<br />
• 6 month trial (of which 12 weeks treatment period)<br />
Primary endpoint<br />
brivaracetam<br />
Adjunctive therapy<br />
Phase 1 Phase 2 Phase 3<br />
Results<br />
H1 2013<br />
Thomas, living with epilepsy<br />
• U.S.: % reduction in POS frequency per 28 days during the 12 week treatment period over placebo<br />
• Europe: 50% responder rate based on a % reduction in POS frequency from baseline to the 12<br />
week treatment period<br />
43
Change language